Headlines about Fibrocell Science (NASDAQ:FCSC) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Fibrocell Science earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 44.2043594055022 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news articles that may have effected Accern’s rankings:
A number of research firms have commented on FCSC. Zacks Investment Research upgraded Fibrocell Science from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research report on Monday. HC Wainwright set a $6.00 price objective on Fibrocell Science and gave the company a “buy” rating in a report on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Fibrocell Science has an average rating of “Buy” and a consensus target price of $3.94.
Shares of Fibrocell Science (FCSC) opened at $0.66 on Tuesday. Fibrocell Science has a 1-year low of $0.61 and a 1-year high of $4.64.
Fibrocell Science (NASDAQ:FCSC) last posted its quarterly earnings data on Monday, November 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.07. equities analysts expect that Fibrocell Science will post -1.63 EPS for the current fiscal year.
In related news, major shareholder Randal J. Kirk purchased 2,727,273 shares of the business’s stock in a transaction on Monday, December 11th. The shares were bought at an average price of $0.77 per share, for a total transaction of $2,100,000.21. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 2.10% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Fibrocell Science (NASDAQ:FCSC) Share Price” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/06/fibrocell-science-fcsc-given-media-sentiment-rating-of-0-06.html.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.